Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
about
Targeted therapy for advanced renal cell carcinomaOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaImmunotherapy for metastatic renal cell carcinoma.Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature.Safety data from randomized controlled trials: applying models for recurrent events.Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan.Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from ASCO 2008.Measuring symptoms as a critical component of drug development and evaluation in hematological diseasesHealth-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alphaContrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma PatientsQuality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in KoreaCharacterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinomaThe STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renaFatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial.Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study.Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.Fatigue in renal cell carcinoma: the hidden burden of current targeted therapiesBaseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.Experience with sunitinib in the treatment of metastatic renal cell carcinomaQuality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.Promiscuous drugs as therapeutics for chemokine receptors.Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfaCombination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer.A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia.Sunitinib for the management of advanced renal cell carcinoma.Sunitinib for metastatic renal cell carcinoma.Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.Sunitinib malate for the treatment of renal cell carcinoma.
P2860
Q24242946-9B99100B-F461-4AC4-BE21-A628A9850B1FQ28247085-74968B6D-DB65-47F0-AE42-3B9860ECD941Q30234458-E9E1D80E-CC7F-4B87-97EF-9BB80EC8A9D2Q30565687-24908A35-43A1-48FB-B03C-8B01B2529D73Q31107512-3A8F280D-D62C-4B8B-B2BF-6E4BAE4C7D20Q33404146-3A8EE22B-184F-4225-970C-A198CD5D54EBQ33410223-B751B694-C909-4FBD-BFF5-F7D665C3242BQ33415035-7A951804-843B-42C4-A2D9-3301B0A2E51AQ33434845-5275DE2D-BCE8-4AEA-867A-2F7D7ED07153Q33455566-56218B09-C3F1-4901-9C95-1D76A9E0EFEBQ33705743-879A75F8-3632-4DDF-AACB-5E3AB960BB41Q33723668-200A1E19-746E-49A4-B16E-8413D16CD5BFQ33847825-5E3C9C0D-8B7A-49E3-A488-829132CA8498Q33869697-96AAD254-C91A-49A4-961A-7F4605D52A28Q33922560-001DD234-1A7F-44C4-B7D5-30557D5A91FFQ33931392-5433C0C7-FEE6-4825-971A-36B6CE821470Q34507381-F29F4881-C6BA-434D-BE19-838AF967B82DQ34513318-14DE3EF4-BD60-44A0-BCC8-2E7B76FC5259Q34998569-BC6ADCB1-600D-4D2E-A64C-39303E9ED99EQ35210611-6AFCB675-5517-4CC2-94F7-AC1D67C7CC82Q35402897-9E075535-03F2-4A05-885E-420B0660B728Q35583812-5DDE9368-C806-4E87-B256-D1C44E4D2D28Q35879829-8AC3AE2B-C304-4B5A-99F9-96DFC58787B9Q35882401-2474B04C-E7C3-4ECC-ACFE-FCADAA03B066Q35949737-7FA52A0A-D41C-423A-8D71-62F9F9ABDAA9Q36067852-360E84C8-3E91-4DDB-BE19-DE43C5731A6CQ36231729-F4432BCB-70D4-45B7-A348-8C5C1C785393Q36625333-A9B3CF78-63B9-4E33-A275-FE914509568EQ37181068-8D86E2AA-22EF-48D6-9E91-03A8A3521EDCQ37362453-3DAAEFB2-DEAF-48F5-A5A0-1C666696410EQ37402151-441E058E-2D94-4D3C-A06E-E5C621753F7EQ37403763-7517D5A5-669E-4FD0-AB3E-7CAFBFED53EDQ37466388-95506D61-182C-47DA-B662-B465C4DBFE9BQ37594615-8B2FAA88-6E0F-4F94-BE0B-6EC47FADA8EDQ37622928-199AADDB-C0DC-45DA-BDDC-0305E7322961Q37705402-345C90C6-4616-4A7A-A606-74C42AECDB19Q37797460-58E66F34-486D-4D23-BDCE-F7E72AA2A3A7Q38002500-F1472A85-8DA8-4929-87A2-0FED061BB2EEQ38004605-9D0D10E6-A224-4BD4-B224-BF031532988FQ38011201-500F42C4-4E31-4980-A750-AE95BAAC5214
P2860
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Quality of life in patients wi ...... a phase III randomized trial.
@en
Quality of life in patients wi ...... a phase III randomized trial.
@nl
type
label
Quality of life in patients wi ...... a phase III randomized trial.
@en
Quality of life in patients wi ...... a phase III randomized trial.
@nl
prefLabel
Quality of life in patients wi ...... a phase III randomized trial.
@en
Quality of life in patients wi ...... a phase III randomized trial.
@nl
P2093
P356
P1476
Quality of life in patients wi ...... a phase III randomized trial.
@en
P2093
Andrew Bushmakin
Claudie Charbonneau
Joseph C Cappelleri
Sindy T Kim
P304
P356
10.1200/JCO.2007.13.5145
P407
P577
2008-08-01T00:00:00Z